Drug updated on 4/18/2024
| Dosage Form | Capsule (oral; 100 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
- Indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Summary
- Acalabrutinib (Calquence) is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and also for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Three studies were reviewed to gather information about Acalabrutinib. These documents provided a comprehensive comparison between Acalabrutinib's efficacy and safety versus other treatments.
- In CLL/SLL cases, Acalabrutinib showed high overall response rate and complete response rate, especially in younger patients under 65, treatment-naive CLL patients, and those receiving combination therapy. However, Zanubrutinib demonstrated higher rates compared to Acalabrutinib monotherapy.
- For frontline CLL treatment in fludarabine-ineligible patients, using network meta-analysis study design revealed that combinations involving Acalabrutinib resulted in significant improvements in progression-free survival compared to all other tested combinations.
- When treating relapsed/refractory MCL cases, it was found that Acalabrutinib increased the overall response rate significantly over several targeted therapies such as Ibrutinib, Bortezomib, Lenalidomide, and Temsirolimus while showcasing a superior progression-free survival advantage over these therapies.
- Despite its effectiveness, particularly when used as part of combination therapies for CLL/SLL and across various metrics for MCL, patient selection considering factors such as age, treatment naivety, and special goals such as response rate or survival, alongside careful consideration of adverse events, remain crucial in optimizing therapeutic outcomes.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Calquence (acalabrutinib) Prescribing Information. | 2022 | AstraZeneca Pharmaceuticals LP, Wilmington, DE |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Chronic lymphocytic leukemia. | 2022 | Alberta Health Services |
| Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 4.2020, NCCN clinical practice guidelines in oncology. | 2020 | Journal of the National Comprehensive Cancer Network |
| Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. | 2020 | Annals of Oncology |